Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer

• Main Authors: Sasan Fazeli MD (Author), Edina Paal MD (Author), Jessica H. Maxwell MD (Author), Kenneth D. Burman MD (Author), Eric S. Nylen MD (Author), Shikha G. Khosla MD, MHA (Author)
• Format: Book
• Published: SAGE Publishing, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Context . Anaplastic thyroid cancer (ATC) is an aggressive tumor with a median survival of 3 to 9 months, a 1-year survival of less than 10% and without definitive therapies. Recently, in BRAF V600E mutated ATCs, new targeted therapy using a combination of a BRAF inhibitor, dabrafenib (Dab), with a...